Related Experiment Videos
Combination macrophage-colony stimulating factor and interferon-gamma administration ameliorates the osteopetrotic
R M Rodriguiz1, L L Key, W L Ries
1Department of Pediatrics, Medical University of South Carolina, Charleston 29425.
Abstract:
Malignant osteopetrosis is a fatal congenital bone disorder characterized by defective osteoclastic function. Death frequently occurs within the first decade of life. The precise molecular defect(s) that causes osteopetrosis is not known. The possibility that osteoclasts, like macrophages, are controlled by interactions with cytokines suggests that these agents may provide a means of increasing osteoclastic function. Macrophage-colony stimulating factor (M-CSF), a cytokine known to enhance macrophage and osteoclast generation, and recombinant human interferon-gamma (rIFN), a cytokine known to stimulate superoxide generation by white cells, were administered to microphthalmic (mi/mi) mice in an attempt to improve the osteopetrotic condition. Each cytokine was administered separately and in combination to neonatal mi/mi mice for 7 consecutive d. Bone turnover, osteoclast numbers, superoxide generation by white cells, and hematocrit were assessed. rIFN, M-CSF, and a combination of the cytokines stimulates oxygen-derived free radical production by white cells and increased bone resorption. rIFN resulted in a reduction in the number of osteoclasts. This reduction in number was ameliorated by M-CSF. M-CSF alone and in combination with rIFN resulted in improved hematopoietic function, increased weight gain, and increased physical activity of the affected mutants.
Insights
Malignant osteopetrosis treatment in mice using cytokines showed promise. Macrophage-colony stimulating factor (M-CSF) and interferon-gamma (IFN) improved bone health and hematopoietic function in affected mice.
Area of Science:
- Immunology
- Bone Biology
- Genetics
Background:
- Malignant osteopetrosis is a fatal congenital bone disorder caused by defective osteoclast function.
- Current molecular defects are unknown, necessitating research into potential therapeutic interventions.
- Cytokine interactions may regulate osteoclast activity, offering a potential treatment avenue.
Purpose of the Study:
- To investigate the therapeutic potential of macrophage-colony stimulating factor (M-CSF) and recombinant human interferon-gamma (rIFN) in a mouse model of malignant osteopetrosis.
- To assess the effects of these cytokines on bone turnover, osteoclast numbers, and hematopoietic function.
Main Methods:
- Neonatal microphthalmic (mi/mi) mice, a model for osteopetrosis, were treated with M-CSF, rIFN, or a combination.
- Cytokine administration occurred daily for 7 consecutive days.
- Assessments included bone turnover, osteoclast counts, white blood cell superoxide generation, and hematocrit.
Main Results:
- Both M-CSF and rIFN, alone and combined, stimulated oxygen-derived free radical production and increased bone resorption.
- rIFN reduced osteoclast numbers, an effect counteracted by M-CSF.
- M-CSF treatment improved hematopoietic function, weight gain, and physical activity in mi/mi mice.
Conclusions:
- Cytokine therapy, particularly with M-CSF, demonstrates potential for managing malignant osteopetrosis by improving bone resorption and hematopoietic function.
- Combined M-CSF and rIFN therapy warrants further investigation for synergistic therapeutic effects in osteopetrosis.